Shattuck Labs CEO acquires 25,610 STTK shares
Shattuck Labs, Inc. director and Chief Executive Officer Taylor Schreiber reported acquiring 25,610 shares of common stock through the exercise of warrants at a conversion price of $1.0846 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Shattuck Labs, Inc. director and Chief Executive Officer Taylor Schreiber reported acquiring 25,610 shares of common stock through the exercise of warrants at a conversion price of $1.0846 per share. Following these transactions, Schreiber holds 122,222 shares directly and 2,610,750 shares indirectly through Houghton Capital Holdings, LLC.
Insider Trade Summary
25,610 shares exercised/converted
Exercise
3 txns
Insider
Schreiber Taylor
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Warrants (Right to Buy) | 25,610 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 25,610 | $1.0846 | $28K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Warrants (Right to Buy) — 0 contracts (Direct);
Common Stock — 122,222 shares (Direct);
Common Stock — 2,610,750 shares (Indirect, By Houghton Capital Holdings, LLC)
Footnotes (2)
- F1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
- F2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Key Figures
Shares acquired via warrants: 25,610 shares
Warrant conversion price: $1.0846 per share
Direct holdings after transaction: 122,222 shares
+3 more
6 metrics
Shares acquired via warrants
25,610 shares
Warrant exercise on 2026-05-12
Warrant conversion price
$1.0846 per share
Exercise price for underlying common stock
Direct holdings after transaction
122,222 shares
Common stock directly owned after Form 4 transactions
Indirect holdings after transaction
2,610,750 shares
Common stock held indirectly via Houghton Capital Holdings, LLC
Private placement unit price
$0.8677 per share and warrant
Price under August 4, 2025 securities purchase agreement
Warrants exercised
25,610 warrants
Derivative exercise converting into common stock
Key Terms
securities purchase agreement, private placement, Warrants, Phase 1 clinical trial, +1 more
5 terms
securities purchase agreement financial
"the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
private placement financial
"the Issuer in a private placement, which closed on August 25, 2025, issued and sold"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Warrants financial
"accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Phase 1 clinical trial medical
"the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data"
A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.
Phase 2 clinical trial(s) medical
"and the design of the planned Phase 2 clinical trial(s) have been announced publicly"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Shattuck Labs (STTK) report for Taylor Schreiber?
Taylor Schreiber reported acquiring 25,610 shares of Shattuck Labs common stock. The acquisition came from exercising warrants into common shares at a stated conversion price, increasing his direct ownership position while also disclosing substantial indirect holdings.
What are Taylor Schreiber’s total direct Shattuck Labs (STTK) holdings after the Form 4?
After the reported transactions, Taylor Schreiber directly holds 122,222 shares of Shattuck Labs common stock. This figure reflects his position immediately following the warrant exercise and related share acquisition disclosed in the Form 4 filing.
What is the background of the warrants exercised in the Shattuck Labs (STTK) Form 4?
The warrants relate to a private placement under an August 4, 2025 securities purchase agreement. Shattuck Labs sold 25,610 common shares and accompanying warrants at $0.8677 per share-and-warrant unit to certain accredited investors, including Taylor Schreiber.
When do the Shattuck Labs (STTK) warrants become exercisable according to the filing?
The warrants are exercisable at any time on or after their original issuance date. This continues until 30 days after Shattuck Labs publicly announces key Phase 1 SL-325 trial data and the design of planned Phase 2 clinical trial or trials.
AI-generated analysis. How Rhea-AI works. Not financial advice.
